Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Royalty Pharma PLC (RPRX) had Stock-Based Compensation of $0.52M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
$568.25M |
|
$238.35M |
|
-- |
|
$568.25M |
|
$34.06M |
|
$534.18M |
|
$-100.75M |
|
$433.43M |
|
$437.71M |
|
$433.43M |
|
$433.43M |
|
$433.43M |
|
$437.71M |
|
$534.18M |
|
$539.46M |
|
435.48M |
|
578.10M |
|
$0.55 |
|
$0.55 |
|
| Balance Sheet Financials | |
$1.84B |
|
$15.03B |
|
$15.77B |
|
$17.61B |
|
$1.18B |
|
$6.62B |
|
$6.64B |
|
$7.82B |
|
$9.79B |
|
$9.79B |
|
$9.79B |
|
961.02M |
|
| Cash Flow Statement Financials | |
$596.08M |
|
$503.92M |
|
$-941.30M |
|
$929.03M |
|
$1.09B |
|
$158.69M |
|
|
Stock-Based Compensation |
$0.52M |
$-233.81M |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.56 |
|
-- |
|
-- |
|
0.40 |
|
0.78 |
|
100.00% |
|
94.01% |
|
94.01% |
|
-- |
|
76.28% |
|
41.94% |
|
$595.02M |
|
-- |
|
-- |
|
-- |
|
0.03 |
|
-- |
|
23.89 |
|
3.77 |
|
4.43% |
|
4.43% |
|
2.46% |
|
2.64% |
|
$10.19 |
|
$1.03 |
|
$1.03 |
|